CERo Therapeutics Holdings Inc
CERO
Company Profile
Business description
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Contact
201 Haskings Way
Suite 230
South San FranciscoCA94080
USAT: +1 650 407-2376
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,775.00 | 4.40 | 0.05% |
| CAC 40 | 7,742.24 | 57.56 | 0.75% |
| DAX 40 | 23,699.12 | 182.89 | 0.78% |
| Dow JONES (US) | 42,515.09 | 317.30 | 0.75% |
| FTSE 100 | 8,875.22 | 24.59 | 0.28% |
| HKSE | 24,060.99 | 168.43 | 0.70% |
| NASDAQ | 19,701.21 | 294.39 | 1.52% |
| Nikkei 225 | 38,311.33 | 477.08 | 1.26% |
| NZX 50 Index | 12,690.13 | 137.26 | 1.09% |
| S&P 500 | 6,033.11 | 56.14 | 0.94% |
| S&P/ASX 200 | 8,548.40 | 1.00 | 0.01% |
| SSE Composite Index | 3,388.73 | 11.73 | 0.35% |